Myriad Genetics: CCO Departs; EVP, Commercial Appointed

What Happened
Myriad Genetics announced an executive change on September 16, 2026: Brian Donnelly no longer serves as Chief Commercial Officer, and the Board appointed Vishal Sikri (previously Senior Vice President, Product) as Executive Vice President, Commercial, effective September 16, 2026. Mr. Donnelly is expected to remain as a non‑executive employee through September 21, 2026 to assist with the transition. The company furnished a press release about the changes as Exhibit 99.1 to the Form 8-K.

Key Details

• Effective date: September 16, 2026 for both the departure and the appointment.
• Transition support: Brian Donnelly will remain in a non‑executive capacity through September 21, 2026.
• Internal promotion: Vishal Sikri moved from SVP, Product to EVP, Commercial.
• Disclosure: The announcement was furnished as a press release (Exhibit 99.1); no compensation terms or other officer changes were disclosed in the filing.

Why It Matters
This 8-K documents a change in commercial leadership, which could affect Myriad’s sales and go‑to‑market execution given the role’s responsibility for commercial operations. The internal promotion suggests continuity in strategy and product-commercial alignment, and the short transition period provides limited overlap for handoff. Investors should note the filing does not include financial terms, compensation changes, or other material items beyond the personnel moves; monitor future reports or press releases for any operational impact on revenue or commercial performance.